Skip to content Skip to footer

News

Latest news from CHV and our portfolio companies 

Featured News

PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage company redefining cancer treatment with therapeutics administered continuously and exclusively at the tumor site, today announced that it has concluded dosing in

Insights & Impacts: The latest from CHV

The round was led by SPRIG Equity with participation from all major Series C investors

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health

PreTRM® test-and-treat strategy demonstrates statistically and clinically significant improvement in neonatal health outcomes and hospital

Data to be presented on February 3rd during a Spotlight Session at AF Symposium 2023

Novel Foam-Based Design Demonstrates Successful LAAO Seal with No Device-Related Thrombus Conformal Medical, Inc., a

Rejoni announced today that it has closed a $25 million Series B financing. The round

– Clinical and economic benefits of the PreTRM® test and treat strategy illustrated amongst diverse

AtaCor Medical, Inc. has announced completion of its second human clinical study of the Extravascular

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health

Seasoned Medical Device Executive, James Reinstein, Appointed as Chief Executive Officer Conformal Medical, Inc., a

Interested in learning more?